Jonathan Karn

Sources

Sources are listed once and connected to each accepted claim they support. Excerpts preserve the source language used in the review.

1. [1]

   Jonathan Karn | Pathology | School of Medicine | Case Western Reserve University

   9 source claims · Reviewed Sep 9, 2026

   Show supporting evidence

   Degree: PhD

   Jonathan Karn, PhD Email [contact withheld] Phone [contact withheld] Fax Number [contact withheld] Professor and Chair, Department of Molecular Biology and Microbiology, School of Medicine Director, Case Center for AIDS Research Professor, Department of Biochemistry, School of Medicine Member, Population and Cancer Prevention Program, Case Comprehensive Cancer Center HIV persists in the face of highly active antiretroviral therapy (HAART) due to constitutive low-level replication in sites that are poorly accessible to drugs and the development of latent infections in a variety of types including the long-lived memory CD4+ T cell population, macrophages, and microglial cells in the brain - cells that play a critical role in neurologic dysfunction and neurotoxicity. Although HAART has greatly extended survival to patients infected with HIV-1, current therapy has failed to decrease the prevalence of HIV-neurological diseases especially in individuals who abuse drugs. Current research interest concerns epigenetic control mechanisms that regulate HIV transcription and latency. Understanding these mechanisms is central to current efforts to induce latent viruses as part of an HIV eradication strategy. We have established new model systems for studying HIV latency and identified novel signaling pathways leading to proviral reactivation and silencing – key insights that support current efforts at HIV eradication and cure. Additional projects include harnessing NK cells to eradicate the latent HIV reservoir. Another theme is studies of HIV infection and latency in microglial cells, a key factor in the development of neurocognitive defects. Finally, we have recently initiated projects on the replication of SARS-CoV-2 using a reverse genetics strategy. We are also developing new diagnostic assays for detection of intracellular SARS-CoV-2 replication.

   Education record: PhD

   Jonathan Karn, PhD

   Identity: Jonathan Karn

   Jonathan Karn, PhD Email [contact withheld] Phone [contact withheld] Fax Number [contact withheld] Professor and Chair, Department of Molecular Biology and Microbiology, School of Medicine Director, Case Center for AIDS Research Professor, Department of Biochemistry, School of Medicine Member, Population and Cancer Prevention Program, Case Comprehensive Cancer Center HIV persists in the face of highly active antiretroviral therapy (HAART) due to constitutive low-level replication in sites that are poorly accessible to drugs and the development of latent infections in a variety of types including the long-lived memory CD4+ T cell population, macrophages, and microglial cells in the brain - cells that play a critical role in neurologic dysfunction and neurotoxicity. Although HAART has greatly extended survival to patients infected with HIV-1, current therapy has failed to decrease the prevalence of HIV-neurological diseases especially in individuals who abuse drugs. Current research interest concerns epigenetic control mechanisms that regulate HIV transcription and latency. Understanding these mechanisms is central to current efforts to induce latent viruses as part of an HIV eradication strategy. We have established new model systems for studying HIV latency and identified novel signaling pathways leading to proviral reactivation and silencing – key insights that support current efforts at HIV eradication and cure. Additional projects include harnessing NK cells to eradicate the latent HIV reservoir. Another theme is studies of HIV infection and latency in microglial cells, a key factor in the development of neurocognitive defects. Finally, we have recently initiated projects on the replication of SARS-CoV-2 using a reverse genetics strategy. We are also developing new diagnostic assays for detection of intracellular SARS-CoV-2 replication.

   Professional role: Director, Case Center for AIDS Research

   Director, Case Center for AIDS Research

   Jonathan Karn, PhD Email [contact withheld] Phone [contact withheld] Fax Number [contact withheld] Professor and Chair, Department of Molecular Biology and Microbiology, School of Medicine Director, Case Center for AIDS Research Professor, Department of Biochemistry, School of Medicine Member, Population and Cancer Prevention Program, Case Comprehensive Cancer Center HIV persists in the face of highly active antiretroviral therapy (HAART) due to constitutive low-level replication in sites that are poorly accessible to drugs and the development of latent infections in a variety of types including the long-lived memory CD4+ T cell population, macrophages, and microglial cells in the brain - cells that play a critical role in neurologic dysfunction and neurotoxicity. Although HAART has greatly extended survival to patients infected with HIV-1, current therapy has failed to decrease the prevalence of HIV-neurological diseases especially in individuals who abuse drugs. Current research interest concerns epigenetic control mechanisms that regulate HIV transcription and latency. Understanding these mechanisms is central to current efforts to induce latent viruses as part of an HIV eradication strategy. We have established new model systems for studying HIV latency and identified novel signaling pathways leading to proviral reactivation and silencing – key insights that support current efforts at HIV eradication and cure. Additional projects include harnessing NK cells to eradicate the latent HIV reservoir. Another theme is studies of HIV infection and latency in microglial cells, a key factor in the development of neurocognitive defects. Finally, we have recently initiated projects on the replication of SARS-CoV-2 using a reverse genetics strategy. We are also developing new diagnostic assays for detection of intracellular SARS-CoV-2 replication.

   Professional role: Professor and Chair, Department of Molecular Biology and Microbiology, School of Medicine

   Professor and Chair, Department of Molecular Biology and Microbiology, School of Medicine

   Jonathan Karn, PhD Email [contact withheld] Phone [contact withheld] Fax Number [contact withheld] Professor and Chair, Department of Molecular Biology and Microbiology, School of Medicine Director, Case Center for AIDS Research Professor, Department of Biochemistry, School of Medicine Member, Population and Cancer Prevention Program, Case Comprehensive Cancer Center HIV persists in the face of highly active antiretroviral therapy (HAART) due to constitutive low-level replication in sites that are poorly accessible to drugs and the development of latent infections in a variety of types including the long-lived memory CD4+ T cell population, macrophages, and microglial cells in the brain - cells that play a critical role in neurologic dysfunction and neurotoxicity. Although HAART has greatly extended survival to patients infected with HIV-1, current therapy has failed to decrease the prevalence of HIV-neurological diseases especially in individuals who abuse drugs. Current research interest concerns epigenetic control mechanisms that regulate HIV transcription and latency. Understanding these mechanisms is central to current efforts to induce latent viruses as part of an HIV eradication strategy. We have established new model systems for studying HIV latency and identified novel signaling pathways leading to proviral reactivation and silencing – key insights that support current efforts at HIV eradication and cure. Additional projects include harnessing NK cells to eradicate the latent HIV reservoir. Another theme is studies of HIV infection and latency in microglial cells, a key factor in the development of neurocognitive defects. Finally, we have recently initiated projects on the replication of SARS-CoV-2 using a reverse genetics strategy. We are also developing new diagnostic assays for detection of intracellular SARS-CoV-2 replication.

   Professional role: Professor, Department of Biochemistry, School of Medicine

   Jonathan Karn, PhD Email [contact withheld] Phone [contact withheld] Fax Number [contact withheld] Professor and Chair, Department of Molecular Biology and Microbiology, School of Medicine Director, Case Center for AIDS Research Professor, Department of Biochemistry, School of Medicine Member, Population and Cancer Prevention Program, Case Comprehensive Cancer Center HIV persists in the face of highly active antiretroviral therapy (HAART) due to constitutive low-level replication in sites that are poorly accessible to drugs and the development of latent infections in a variety of types including the long-lived memory CD4+ T cell population, macrophages, and microglial cells in the brain - cells that play a critical role in neurologic dysfunction and neurotoxicity. Although HAART has greatly extended survival to patients infected with HIV-1, current therapy has failed to decrease the prevalence of HIV-neurological diseases especially in individuals who abuse drugs. Current research interest concerns epigenetic control mechanisms that regulate HIV transcription and latency. Understanding these mechanisms is central to current efforts to induce latent viruses as part of an HIV eradication strategy. We have established new model systems for studying HIV latency and identified novel signaling pathways leading to proviral reactivation and silencing – key insights that support current efforts at HIV eradication and cure. Additional projects include harnessing NK cells to eradicate the latent HIV reservoir. Another theme is studies of HIV infection and latency in microglial cells, a key factor in the development of neurocognitive defects. Finally, we have recently initiated projects on the replication of SARS-CoV-2 using a reverse genetics strategy. We are also developing new diagnostic assays for detection of intracellular SARS-CoV-2 replication.

   Professor, Department of Biochemistry, School of Medicine

   Official profile: Official profile

   Jonathan Karn, PhD Email [contact withheld] Phone [contact withheld] Fax Number [contact withheld] Professor and Chair, Department of Molecular Biology and Microbiology, School of Medicine Director, Case Center for AIDS Research Professor, Department of Biochemistry, School of Medicine Member, Population and Cancer Prevention Program, Case Comprehensive Cancer Center HIV persists in the face of highly active antiretroviral therapy (HAART) due to constitutive low-level replication in sites that are poorly accessible to drugs and the development of latent infections in a variety of types including the long-lived memory CD4+ T cell population, macrophages, and microglial cells in the brain - cells that play a critical role in neurologic dysfunction and neurotoxicity. Although HAART has greatly extended survival to patients infected with HIV-1, current therapy has failed to decrease the prevalence of HIV-neurological diseases especially in individuals who abuse drugs. Current research interest concerns epigenetic control mechanisms that regulate HIV transcription and latency. Understanding these mechanisms is central to current efforts to induce latent viruses as part of an HIV eradication strategy. We have established new model systems for studying HIV latency and identified novel signaling pathways leading to proviral reactivation and silencing – key insights that support current efforts at HIV eradication and cure. Additional projects include harnessing NK cells to eradicate the latent HIV reservoir. Another theme is studies of HIV infection and latency in microglial cells, a key factor in the development of neurocognitive defects. Finally, we have recently initiated projects on the replication of SARS-CoV-2 using a reverse genetics strategy. We are also developing new diagnostic assays for detection of intracellular SARS-CoV-2 replication.

   Research interests: Current research interest concerns epigenetic control mechanisms that regulate HIV transcription and latency.

   Current research interest concerns epigenetic control mechanisms that regulate HIV transcription and latency.

   Research interests: projects on the replication of SARS-CoV-2 using a reverse genetics strategy

   Finally, we have recently initiated projects on the replication of SARS-CoV-2 using a reverse genetics strategy.